By: King of Hemphill, et al. H.B. No. 428
        (Senate Sponsor - Zaffirini)
         (In the Senate - Received from the House April 13, 2021;
  April 13, 2021, read first time and referred to Committee on
  Business & Commerce; May 20, 2021, reported favorably by the
  following vote:  Yeas 9, Nays 0; May 20, 2021, sent to printer.)
Click here to see the committee vote
 
 
A BILL TO BE ENTITLED
 
AN ACT
 
  relating to health benefit plan coverage for ovarian cancer testing
  and screening.
         BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
         SECTION 1.  Section 1370.003(b), Insurance Code, is amended
  to read as follows:
         (b)  Coverage required under this section includes at a
  minimum:
               (1)  a CA 125 blood test; [and]
               (2)  a conventional Pap smear screening or a screening
  using liquid-based cytology methods, as approved by the United
  States Food and Drug Administration, alone or in combination with a
  test approved by the United States Food and Drug Administration for
  the detection of the human papillomavirus; and
               (3)  any other test or screening approved by the United
  States Food and Drug Administration for the detection of ovarian
  cancer.
         SECTION 2.  Section 1370.003, Insurance Code, as amended by
  this Act, applies only to a health benefit plan delivered, issued
  for delivery, or renewed on or after January 1, 2022. A health
  benefit plan delivered, issued for delivery, or renewed before
  January 1, 2022, is governed by the law as it existed immediately
  before the effective date of this Act, and that law is continued in
  effect for that purpose.
         SECTION 3.  This Act takes effect September 1, 2021.
 
  * * * * *